Following agreement by the respective boards of directors, Thermo Fisher Scientific in mid-October announced plans to acquire Olink Holding for US$3.1 billion. The acquisition will enable Thermo Fisher to expand into proteomics and complement its platforms in life sciences and mass spectrometry. Olink offers solutions for advanced proteomics discovery and development.
During preparations for the construction of two new cleanroom facilities, NorthX Biologics, a leading Swedish biological drug manufacturer and process developer, reviewed its environmental monitoring and control procedures, and decided to switch to a new Vaisala system, including almost 150 monitoring locations within cleanrooms and associated facilities.
HeartBeat.bio AG, a biotech company building a highly scalable human organoid and AI-supported drug discovery platform for heart disease, has closed a €4.5 million pre-series A round co-led by i&i Biotech Fund, Invest AG, aws Gründungsfonds II, and Tensor Ventures. The financing enables the completion of a ready-to-use, fully integrated, automated, high-throughput Cardioid Drug Discovery […]
Belgium-based Cerba Research, a leading global clinical trial laboratory service provider owned by Cerba HealthCare, is transforming into a multi-specialist and central laboratory company, providing research organisations with even greater access to exceptional scientific and technical teams in multiple therapeutic areas for drug and vaccine development.
By Dr Jacqueline Gosink Autoimmune neurology is a rapidly growing field driven by the ongoing discovery of novel neural autoantibodies associated with recognizable clinical syndromes. These diseases can affect the central, peripheral and autonomic nervous systems and may co-occur with cancer. Today’s testing landscape encompasses more than 60 neural autoantibodies targeting different intracellular proteins, receptors […]
By Dr F. van Delft, Dr M. Schuurbiers, Dr van den Heuvel and Dr H. van Rossum The development of immunotherapy and other targeted therapies has given rise to significant improvements in the treatment of non-small cell lung cancer. However, some patients do not benefit from these therapies and it is, therefore, important for a […]
We all know that detecting cancer early is the key to obtaining the best treatment outcomes. However, how do you do this when some sectors of the population struggle to access healthcare and does point-of care testing make it possible to take health screening to the people who need it? CLI caught up with Professor […]
TRIMERO Diagnostics offers IVD CE marked Retinol Binding Protein assays, for serum and urine samples, available for nephelometers and the most popular Clinical Chemistry analyzers present on the market.
Powerful and comprehensive health monitoring platform now offers FDA-cleared biomarkers for pulse and respiratory rate
– Excellent accurate measurement in molarity of Lp(a) ( nmol/L ) – Alternative measurement in mass ( mg/ dL ) – Isoform-insensitive test with harmonized reagent and calibrators – Liquid-stable and ready-to-use system reagent – Standardized to international WHO-IFCC reference material SRM2B – DiaSys Lp(a) 21 FS applicable on any clinical chemistry analyzer
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
